81 related articles for article (PubMed ID: 21799462)
1. Genome-wide association study of epirubicin-induced leukopenia in Japanese patients.
Srinivasan Y; Sasa M; Honda J; Takahashi A; Uno S; Kamatani N; Kubo M; Nakamura Y; Zembutsu H
Pharmacogenet Genomics; 2011 Sep; 21(9):552-8. PubMed ID: 21799462
[TBL] [Abstract][Full Text] [Related]
2. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.
Low SK; Kiyotani K; Mushiroda T; Daigo Y; Nakamura Y; Zembutsu H
J Hum Genet; 2009 Oct; 54(10):564-71. PubMed ID: 19696793
[TBL] [Abstract][Full Text] [Related]
3. Association between single-nucleotide polymorphisms in the SEC8L1 gene, which encodes a subunit of the exocyst complex, and rheumatoid arthritis in a Japanese population.
Hamada D; Takata Y; Osabe D; Nomura K; Shinohara S; Egawa H; Nakano S; Shinomiya F; Scafe CR; Reeve VM; Miyamoto T; Moritani M; Kunika K; Inoue H; Yasui N; Itakura M
Arthritis Rheum; 2005 May; 52(5):1371-80. PubMed ID: 15880602
[TBL] [Abstract][Full Text] [Related]
4. [Results of clinical study with epirubicin hydrochloride injectable solution in hepatoma].
Monden M; Nakamura H; Yayoi E; Monden T; Ohi H; Arisawa J; Masuzawa M; Shimizu T; Tomono N; Seki K; Nakao N; Todo A; Inoue Y; Sakon M; Ohsaki Y; Hosoki T
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1713-9. PubMed ID: 9757197
[TBL] [Abstract][Full Text] [Related]
5. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
[TBL] [Abstract][Full Text] [Related]
6. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C; Pfeil AM; Maggen C; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
Breast Cancer Res Treat; 2015 Jul; 152(1):67-76. PubMed ID: 26017071
[TBL] [Abstract][Full Text] [Related]
7. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
[TBL] [Abstract][Full Text] [Related]
8. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.
Sugishita M; Imai T; Kikumori T; Mitsuma A; Shimokata T; Shibata T; Morita S; Inada-Inoue M; Sawaki M; Hasegawa Y; Ando Y
Breast Cancer; 2016 Mar; 23(2):195-201. PubMed ID: 25008867
[TBL] [Abstract][Full Text] [Related]
10. Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients.
Suga T; Ishikawa A; Kohda M; Otsuka Y; Yamada S; Yamamoto N; Shibamoto Y; Ogawa Y; Nomura K; Sho K; Omura M; Sekiguchi K; Kikuchi Y; Michikawa Y; Noda S; Sagara M; Ohashi J; Yoshinaga S; Mizoe J; Tsujii H; Iwakawa M; Imai T
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):685-93. PubMed ID: 17889263
[TBL] [Abstract][Full Text] [Related]
11. A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy.
Kiyotani K; Uno S; Mushiroda T; Takahashi A; Kubo M; Mitsuhata N; Ina S; Kihara C; Kimura Y; Yamaue H; Hirata K; Nakamura Y; Zembutsu H
Pharmacogenet Genomics; 2012 Apr; 22(4):229-35. PubMed ID: 22293537
[TBL] [Abstract][Full Text] [Related]
12. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
13. [Neoadjuvant intraarterial chemotherapy with dose intensification in locally advanced breast cancer].
Takatsuka Y; Shin E; Fukuda K; Mishima H; Tono T; Yagyuu T; Kobayashi K; Kikkawa N
Gan To Kagaku Ryoho; 1995 Sep; 22(11):1546-8. PubMed ID: 7574755
[TBL] [Abstract][Full Text] [Related]
14. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis.
Pearce CL; Hirschhorn JN; Wu AH; Burtt NP; Stram DO; Young S; Kolonel LN; Henderson BE; Altshuler D; Pike MC
J Natl Cancer Inst; 2005 Jan; 97(1):51-9. PubMed ID: 15632380
[TBL] [Abstract][Full Text] [Related]
15. Poor replication of candidate genes for major depressive disorder using genome-wide association data.
Bosker FJ; Hartman CA; Nolte IM; Prins BP; Terpstra P; Posthuma D; van Veen T; Willemsen G; DeRijk RH; de Geus EJ; Hoogendijk WJ; Sullivan PF; Penninx BW; Boomsma DI; Snieder H; Nolen WA
Mol Psychiatry; 2011 May; 16(5):516-32. PubMed ID: 20351714
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
Hui R; Zhang M; Hao XM; Zhang J
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):871-4. PubMed ID: 18396651
[TBL] [Abstract][Full Text] [Related]
17. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.
Kiyotani K; Mushiroda T; Kubo M; Zembutsu H; Sugiyama Y; Nakamura Y
Cancer Sci; 2008 May; 99(5):967-72. PubMed ID: 18294295
[TBL] [Abstract][Full Text] [Related]
18. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
Venturini M; Del Mastro L; Aitini E; Baldini E; Caroti C; Contu A; Testore F; Brema F; Pronzato P; Cavazzini G; Sertoli MR; Canavese G; Rosso R; Bruzzi P
J Natl Cancer Inst; 2005 Dec; 97(23):1724-33. PubMed ID: 16333028
[TBL] [Abstract][Full Text] [Related]
19. Increased dosage of epirubicin and mitomycin-C for the treatment of metastatic adenocarcinoma of unknown primary site.
Polyzos A; Koulentianos E; Tzianoumis L; Sfikakis P
J Chemother; 1989 Jul; 1(4 Suppl):1185-6. PubMed ID: 16312826
[No Abstract] [Full Text] [Related]
20. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
